NEW YORK (GenomeWeb News) – Vancouver-based molecular diagnostics technologies developer GenomeDx Biosciences has closed an undisclosed amount of Series A round of financing.
The company said on Monday that the funding was led by Baird Venture Partners and Aeris Capital AG. The round includes investments from CD Ventures and other individual investors.
Founded in 2007 by Tim Triche, a member of BVP's advisory board, GenomeDx develops and sells molecular diagnostic tests and clinical support tools for personalized medicine applications in clinical cancer care.